Found 11 matching trials
Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59
PHASE1This research will study safety and the body's immune (defense system) resp...
Location
Emory Children's Center - Pediatric Infectious Diseases
Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years
PHASE3The purpose of this Phase 3, observer-blind, placebo-controlled, multi-cent...
Location
GSK Investigational Site
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
PHASE3The present study, phase III, randomized, controlled, observer-blind, multi...
Location
Tampere Vaccine Research Clinic (15 sites)
Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years
PHASE2The purpose of this study is to determine whether GSK's avian flu vaccine G...
Location
GSK Investigational Site
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above
PHASE3Today, the leading contender for the next pandemic of influenza is H5N1, a ...
Location
GSK Investigational Site
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Healthy Adults
PHASE2Evaluate Safety, Tolerability and Immune Response of Adjuvanted H5N1 Cell C...
Location
1 Miami Research Associates
Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine
PHASE2This trial will assess the immunogenicity and safety elicited by the adjuva...
Location
GSK Investigational Site
Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP)
PHASE1Study SP-1219-007 is a multi-centre, randomised, study designed to access t...
Location
University of Sunshine Coast Clinical Trials
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
PHASE3This study will assess safety and immunogenicity of GSK Biologicals' H5N1 f...
Location
GSK Investigational Site
Study of Different Formulations of an Intramuscular A/H5N1 Inactivated, Split Virion Influenza Adjuvanted Vaccine
PHASE1Following the licensure of sanofi pasteur's 90 µg rgA/Vietnam/1203/2004 pan...
Location
Multiple Locations